跳至主要内容
临床试验/EUCTR2020-001306-35-FR
EUCTR2020-001306-35-FR进行中(未招募)1 期

Protective role of inhaled steroids for COVID-19 infection - INHASCO

DRCI APHP0 个研究点开始时间: 2020年3月27日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Patient = 18 years old
  • -Laboratory proved infection by COVID-19 within 2 days
  • -Hospitalization is required (based on investigator judgement)
  • -Patient affiliated to a social security regime
  • -Patient able to give free, informed and written consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 436
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 436

排除标准

  • -Current treatment with any inhaled steroid
  • (any other form of steroid administration does not exclude the patient)
  • -Intensive care unit is required for the patient
  • (based on investigator judgement)
  • -Patient with cognitive impairment which do not guarantee proper use of the treatment by the patient himself
  • -Pregnant or breastfeeding women
  • -Participation in another interventional drug study involving human participants and concerning COVID-19 infection or being in the exclusion period of a previous study involving human participants
  • -Contraindications to the treatments
  • -Not to be resuscitated decision (co-morbidity, …)

研究者

发起方
DRCI APHP

相似试验